EUVIMEDEUVIMED entdecken
LeserbriefOpen Access · CC BY-NC 3.0

Interpreting Perineural Esketamine for Analgesia After Total Knee Arthroplasty: Methodological and Reporting Considerations [Letter]

Zijin Zhou, Yanxin Li, Jun Lu iD

Drug Design, Development and Therapy · 2026-07 · Volume 20 · 1-3

DOI: 10.2147/dddt.s642165 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Drug Design, Development and Therapy, 2026-07. Verfasst von Zijin Zhou und 2 weiteren Autor:innen. Beteiligte Einrichtung: Graduate School, Tianjin University of Traditional Chinese Medicine, Tianjin, People's Republic of China. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We read with interest the randomized, double-blind trial by Cheng et al comparing ultrasound-guided femoral nerve block with ropivacaine alone versus ropivacaine plus perineural esketamine in 60 patients undergoing total knee arthroplasty.1 The authors reported a lower visual analogue scale (VAS) score at 10 hours and reduced 24-hour sufentanil consumption with esketamine, concluding that the regimen could serve as a safe analgesic option.The opioidconsumption finding appears statistically robust, but several internal reporting and analytical issues limit the strength of the claims regarding improved pain control, safety, and a specifically perineural mechanism. Inconsistent Pain-Assessment Timing and Unadjusted Repeated TestingThe VAS schedule is inconsistent across the article.The abstract lists assessments at 2, 4, 6, 8, 10, and 12 hours; the Outcome Measurements section lists 2, 4, 6, 8, 12, and 24 hours; and Table 2 reports 2, 4, 6, 8, 10, and 12 hours.Thus, the 24-hour assessment specified in the main Methods is absent, whereas a 10-hour assessment not specified there is included.This discrepancy is consequential because 10 hours is the only time point showing a between-group difference (P=0.026).Clarification against the time-stamped trial registry and protocol is needed to establish the prespecified schedule and to recover the omitted 24-hour result, if collected.The six VAS time points were analyzed using separate Mann-Whitney tests without a declared primary VAS time point, a global longitudinal test, or an adjustment for repeated testing.An illustrative Bonferroni adjustment across the six comparisons would change P=0.026 to P=0.156.Bonferroni correction is not the only possible approach, particularly because repeated measurements are correlated, but the present series of isolated tests does not estimate an overall treatment trajectory or a group-by-time interaction.2,3 A mixed-effects model, repeated-measures model, or prespecified area-under-the-curve analysis, followed by multiplicity-controlled visit-specific contrasts, would provide a more coherent assessment.Until such an analysis is reported, the isolated 10-hour result should be considered exploratory rather than evidence of consistently improved postoperative pain.

Autor:innen und Institutionen

  • Graduate School, Tianjin University of Traditional Chinese Medicine, Tianjin, People's Republic of China.
  • Medical School, Tianjin University, Tianjin, People's Republic of China.
  • Department of Orthopedics, Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital, Tianjin, People's Republic of China.

ORCID-Profile: Jun Lu

Zitieren

APA

Zhou, Z., Li, Y., & Lu, J. (2026). Interpreting Perineural Esketamine for Analgesia After Total Knee Arthroplasty: Methodological and Reporting Considerations [Letter]. Drug Design, Development and Therapy, Volume 20, 1-3. https://doi.org/10.2147/dddt.s642165

Vancouver

Zhou Z, Li Y, Lu J. Interpreting Perineural Esketamine for Analgesia After Total Knee Arthroplasty: Methodological and Reporting Considerations [Letter]. Drug Design, Development and Therapy. 2026;Volume 20:1-3. doi:10.2147/dddt.s642165

BibTeX
@article{Zhou2026,
  author = {Zhou, Zijin and Li, Yanxin and Lu, Jun},
  title = {Interpreting Perineural Esketamine for Analgesia After Total Knee Arthroplasty: Methodological and Reporting Considerations [Letter]},
  journal = {Drug Design, Development and Therapy},
  year = {2026},
  volume = {Volume 20},
  pages = {1--3},
  doi = {10.2147/dddt.s642165}
}
Kostenlos starten →